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ABSTRACT
Asparaginase is an integral component of multiagent chemotherapy regimens for the treatment of
children with acute lymphoblastic leukemia. Positive outcomes are seen in patients who are able to
complete their entire prescribed course of asparaginase therapy. Toxicities associated with
asparaginase use include hypersensitivity (clinical and subclinical), pancreatitis, thrombosis,
encephalopathy, and liver dysfunction. Depending on the nature and severity of the toxicity,
asparaginase therapy may be altered or discontinued in some patients. Clinical hypersensitivity is
the most common asparaginase-associated toxicity requiring treatment discontinuation, occurring
in up to 30% of patients receiving Escherichia coli–derived asparaginase. The ability to rapidly
identify and manage asparaginase-associated toxicity will help ensure patients receive the maximal
benefit from asparaginase therapy. This review will provide an overview of the common toxicities
associated with asparaginase use and recommendations for treatment management.
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Introduction
With current multiagent chemotherapy regimens,
long-term outcomes for children with acute lympho-
blastic leukemia (ALL) have greatly improved, with
reported overall survival rates 490% compared with
530% in the 1960s [1,2]. These substantial gains in
survival are due, at least in part, to the increased use of
intense and prolonged asparaginase therapy [3–5].
However, asparaginase use is associated with a
number of toxicities. Failure to receive the full course
of asparaginase therapy due to treatment-emergent
toxicity has been associated with poor outcomes in
children with ALL [3,6–8]. This review provides a concise
overview of common toxicities associated with aspar-
aginase therapy and recommendations for
management.
Mechanism of action of asparaginase
The administration of asparaginase reduces plasma
asparagine concentrations by catalyzing the
deamination of asparagine into aspartic acid and
ammonia [8]. At sufficient enzyme activity levels,
asparaginase therapy results in the complete depletion
of serum asparagine concentrations, depriving leukemic
blasts of this amino acid [9], resulting in reduced protein
synthesis and ultimately leukemic cell death.
Three different asparaginase preparations are cur-
rently used for the treatment of patients with ALL. Two
preparations, native Escherichia coli (E. coli) asparaginase
and polyethylene glycolated (PEG)-asparaginase, are
derived from the bacterium E. coli [10]. Native E. coli
asparaginase has been widely used as a first-line
treatment in ALL; however, the supply of this prepar-
ation has recently ceased in the United States and has
largely been replaced with PEG-asparaginase [11]. The
third preparation, Erwinia asparaginase, is derived from
the bacterium Erwinia chrysanthemi [12]. The distinct
bacterial origins of Erwinia asparaginase give it a unique
immunogenic profile, showing no cross-reactivity with
native E. coli asparaginase or PEG-asparaginase [13].
Erwinia asparaginase is indicated as a component of a
multiagent chemotherapy regimen for the treatment of
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patients with ALL who have developed hypersensitivity
to E. coli–derived asparaginases [14]. Each of the three
asparaginase preparations displays markedly different
pharmacokinetics that must be accounted for when
determining dosing schedules [15]. The half-life of
PEG-asparaginase has been estimated at 4.8–7.0 days
and is longer than that reported with native E. coli
asparaginase and Erwinia asparaginase [16–19]. In com-
parison, the half-life of native E. coli asparaginase and
Erwinia asparaginase are 1.28 days and 15.6 hours,
respectively [14,19]. Due to the shorter half-life of
Erwinia asparaginase, patients who switch to this
formulation should receive a higher dose at a greater
frequency in order to maintain therapeutic levels of
asparagine depletion [20].
Asparaginase toxicity
Hypersensitivity
The asparaginases used in ALL treatment protocols are
large molecules of bacterial origin, and thus have the
ability to elicit an immune response in patients [8].
Immune reactions to asparaginase are classified as either
clinical or subclinical hypersensitivity (also referred to as
‘‘silent inactivation’’). Clinical hypersensitivity is one of
the most common reasons for the discontinuation of
asparaginase therapy.
Rates of clinical hypersensitivity reactions in the
literature vary. Clinical hypersensitivity to native E. coli
asparaginase has been reported in up to 75% of patients
with ALL [21], although rates generally range from
10–30% [7,22–26]. Clinical hypersensitivity reactions
appear to be less prevalent with PEG-asparaginase,
with rates from 3–24% reported in clinical trials
[3,7,24,26]. Hypersensitivity reactions to PEG-asparagi-
nase are more common when patients have been
previously exposed to native E. coli asparaginase,
owing to their common bacterial source [27].
Rates of clinical hypersensitivity in patients receiving
Erwinia asparaginase, which is derived from an alterna-
tive bacterial source, have been reported in 3–37% of
patients in clinical trials [7,14,20,26,28–34]. Patients who
develop clinical hypersensitivity to asparaginase have
shown increased antibody formation and decreased
asparaginase activity levels compared with patients who
do not develop hypersensitivity [32,35,36]. Tong and
colleagues [32] reported clinical hypersensitivity (grades
1–4) in 20 of 89 patients (22%) administered
PEG-asparaginase during the intensification phase after
receiving native E. coli asparaginase during the induction
phase of the Dutch Childhood Oncology Group (DCOG)
ALL-10 protocol. All 20 patients with hypersensitivity
showed PEG-asparaginase activity levels of 0 IU/L, and
E. coli antibodies were found in all patients with
hypersensitivity during intensification.
The likelihood of asparaginase eliciting an immune
response in patients may be influenced by a number of
factors, including the asparaginase preparation, treat-
ment intensity, and use of concomitant medications
[23,24,29,36,48]. The risk of antibody formation for
patients increases with repeated exposure to asparagi-
nase; consolidation and reinduction phases of treatment
show the greatest incidence of hypersensitivity reactions
and antibody formation [30,49]. However, prolonged
exposure to asparaginase, without gaps in treatment,
has been associated with decreased antibody levels
[36,50]. Due to this, hypersensitivity reactions are most
common within the first few doses of asparaginase after
a break in treatment [32]. Additionally, the concomitant
administration of corticosteroids has been associated
with reduced signs of clinical hypersensitivity [24,25].
However, as clinical hypersensitivity is often the only
observable symptom of antibody formation, suppression
of these symptoms may only mask signs of hypersen-
sitivity and result in prolonged periods of suboptimal
asparaginase activity levels in patients. Whenever pos-
sible, therapeutic dose monitoring of asparaginase
activity levels should be utilized to identify patients
with suboptimal activity levels to adjust treatment in
these patients accordingly [32].
Patients who display a hypersensitivity reaction to an
E. coli–derived asparaginase should immediately discon-
tinue their current therapy and be switched to Erwinia
asparaginase (Table I) [33, 37]. Patients with hypersen-
sitivity switched to Erwinia asparaginase show thera-
peutic levels of asparaginase activity, and the majority of
patients with hypersensitivity are able to complete their
prescribed course of treatment [33]. The FDA-approved
dose substitution of Erwinia asparaginase for each
planned dose of PEG-asparaginase is 25,000 IU/m2
administered intramuscularly (IM) or intravenously (IV)
3 times a week (Monday/Wednesday/Friday) for six
doses [14]. No established guidelines exist for when
treatment with the new preparation should be initiated
in patients who switch asparaginase preparations
because of clinical hypersensitivity. In practice, many
patients with hypersensitivity begin treatment with the
new preparation at the time of their next scheduled
dose. Given the strong association between clinical
hypersensitivity and reduced asparaginase activity [32],
this practice may result in suboptimal asparagine
depletion in the patients between doses. To avoid a
prolonged gap in asparagine depletion, patients with
hypersensitivity to asparaginase should begin treatment
with an alternative asparaginase as early as possible,
preferably within 48–72 hours after the hypersensitivity
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event if symptoms are fully resolved [51,52]. Patients
who develop hypersensitivity to both E. coli– and
Erwinia chrysanthemi–derived formulations are forced
to discontinue asparaginase treatment [32].
Subclinical hypersensitivity is characterized by the
development of antiasparaginase antibodies and sig-
nificantly reduced asparaginase activity levels [19,37].
Although difficult to identify because of the lack of
clinical symptoms, subclinical hypersensitivity has
been reported in 8–29% of patients receiving E.
coli–derived asparaginases [25,32,37]. Subclinical
hypersensitivity is strongly associated with poor clin-
ical outcomes if not readily identified and addressed
[25,37]. The ability to prospectively identify patients
with subclinical hypersensitivity and switch these
patients to an alternate asparaginase formulation has
been associated with improved outcomes in a clinical
trial [37].
Following the IV administration of asparaginase,
localized non-antibody-mediated infusion reactions
may occur in patients [53]. Unlike true clinical hyper-
sensitivity reactions, patients who display an infusion
reaction to asparaginase do not show antiasparaginase
antibodies and infusion reactions are not associated
with a decrease in asparaginase activity levels. Patients
with a non-antibody-mediated infusion reaction to
asparaginase may be rechallenged with a longer
infusion duration and appropriate premedication.
Differentiating between clinical hypersensitivity, sub-
clinical hypersensitivity, and non-antibody-mediated
infusion reactions can be difficult in practice. But
measurement of asparaginase activity levels might
help to differentiate between these reactions.
Hyperglycemia
The use of asparaginase is associated with reduced
insulin production and possibly a decrease in the
expression of insulin receptors [38,54]. Corticosteroid
use is associated with greater insulin resistance and an
increase in hepatic gluconeogenesis [55,56].
Hyperglycemia is more common during phases of
therapy when asparaginase and corticosteroids are
administered together and in relatively higher doses
[38,57].
Asparaginase-associated hyperglycemia has been
reported in 4–20% of pediatric patients receiving E. coli
asparaginase for ALL [57–60] and in 4–17% of patients
receiving Erwinia asparaginase [14,33,34]. The aspar-
aginase preparation and the type of corticosteroid
(prednisone or dexamethasone) used in treatment do
not seem to influence the risk of hyperglycemia
[24,58,60]. Insulin therapy may be required in severeTa
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cases; however, asparaginase therapy can continue if the
patient shows normal glucose levels (5200mg/dL or
11mmol/L) with insulin [Table I] [8,38,40]. The final
decision regarding the continuation of asparagainse
should be made by the treating physician based on the
patient’s general status.
Pancreatitis
While the precise pathogenesis of pancreatitis is
unknown, the reduction in protein synthesis resulting
from asparaginase-induced depletion of asparagine has
been implicated [61]. In clinical trials, pancreatitis has
been reported in 2–18% of patients undergoing
asparaginase therapy for ALL, with grade 3/4 pancreatitis
occurring in 5–10% of patients [39,61–65]. The formula-
tion of asparaginase does not influence the incidence of
pancreatitis in patients [61].
Diagnosis of pancreatitis is based on a combination of
clinical, biochemical (amylase, lipase), and radiological
evidence. Asparaginase therapy can be continued with
mildly elevated amylase or lipase levels if clinical signs
are absent; however, asparaginase treatment is generally
discontinued in the case of severe pancreatitis [Table I]
[39,40]. Patients with mild pancreatitis may be rechal-
lenged with asparaginase if within 48 hours the patient
displays no clinical symptoms, amylase and lipase levels
are below 3 times the upper limit of normal (ULN), and
there are no signs of pseudocysts or necrosis on imaging
[61]. Caution should be exercised, as recurrence of
pancreatitis has been reported in up to 63% of patients
following re-exposure to asparaginase [62].
Thrombosis
Asparaginase is associated with a decrease in the
production of a number of proteins involved in coagu-
lation and fibrinolysis, and may increase the risk of
thrombosis or bleeding [66–70]. The majority of
asparaginase-associated thrombotic events occur
during induction and are likely attributable to multiple
factors, including indwelling central venous catheter,
treatment with corticosteroids, treatment with asparagi-
nase, and leukemia itself [41,71]. The incidence of
symptomatic thrombosis ranges from 2–7% in clinical
trials and has been reported with both E. coli– and
Erwinia-derived asparaginase [14,33,34,41,71–73]. A
meta-analysis of 17 studies focused on thrombotic
complications in children with ALL found that the overall
incidence of thrombosis is 5.2% [71]. The authors report
that the majority of events (53.8%) occurred in the
central nervous system (CNS), and 28.6% of the total
events were classified as central venous thrombosis. Of
the non-CNS events, the greatest incidence was seen in
the upper limbs and was categorized as deep venous
thrombosis and central venous catheter–related [71].
Patients with deep venous thrombosis should be
managed with anticoagulation therapy, preferably with
low-molecular-weight heparin (LMWH) [42].
Asparaginase use should be temporarily discontinued
in the case of clinically significant bleeding or throm-
botic events; however, reports suggest that re-exposure
to asparaginase with LMWH is safe and feasible in
patients who develop thrombosis once clinical symp-
toms have resolved [Table I] [43,73]. Screening patients
for prothrombotic risk factors has been suggested in
some reports [71]; however, the evidence linking
thrombophilia and other risk factors to the incidence
of thrombotic events is mixed [74–78].
Encephalopathy
Encephalopathy has been reported in patients receiving
asparaginase treatment for ALL, although the precise
relationship between asparaginase and neurotoxicity is
unclear [40,44,79,80]. Posterior reversible encephalop-
athy is one of the encephalopathies sometimes seen in
patients with ALL. The majority of reported cases of
posterior reversible encephalopathy in patients with ALL
occur during induction treatment, which could also be
related to hypertension caused by glucocorticoids, and
resolve without serious complications in most cases.
[80–83].
Elevated plasma ammonia levels, due to the aspar-
aginase-driven breakdown of asparagine into aspartic
acid and ammonia, are sometimes associated with
encephalopathy in patients undergoing asparaginase
therapy [79,80,84]; however, hyperammonemia alone
does not typically result in symptoms, and reduced
expression of the glutamine transporter proteins may
also play a role [85]. Patients with existing liver disease
may be at an increased risk for developing symptoms of
hyperammonemia. There is no standard therapy for
patients with asparaginase-induced hyperammonemia.
Treatments with decreased protein intake, lactulose
treatment, benzoic acid, and arginine and sodium
phenylbutyrate have been reported; however, there is
sparse evidence for these treatments and their efficacy is
unclear [84,86,87].
Myelosuppression
Although a number of early studies described an
association between asparaginase use and myelosup-
pression [88,89], asparaginase itself is not typically
considered a myelosuppressive agent. Asparaginase
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may cause myelosuppression directly or indirectly by
altering the myelosuppressive effects of other agents,
such as methotrexate (MTX) or 6-mercaptopurine (6-MP)
[45,90,91]. A recent report of pediatric patients
(510 years of age) with ALL treated on the Dana-
Farber Cancer Institute ALL Consortium Protocol 05-01
found increased myelosuppression during prolonged
asparaginase therapy in consolidation [45]. Patients
received 30 weeks of asparaginase treatment during
consolidation, but no asparaginase was administered
during continuation. A greater percentage of patients
required dose reductions of MTX and/or 6-MP during
consolidation compared with continuation (24% vs. 9%,
respectively), suggesting a myelosuppressive role of
asparaginase. Dose reduction of concurrently adminis-
tered myelosuppressive agents may be used to man-
age asparaginase-associated myelosuppression during
consolidation (Table I)[45].
Hypertriglyceridemia
Asparaginase use is associated with a number of
abnormalities in lipid metabolism, including hypertrigly-
ceridemia [8,92]. Corticosteroids are adipokinetic agents
that alter lipid synthesis, clearance, and metabolism, and
thus contribute to a transient elevation of triglyceride
levels [92,93]. Transient elevations in triglyceride levels
are most often seen when patients receive high doses of
asparaginase and corticosteroids [94]. Combined treat-
ment with asparaginase and corticosteroids leads to
hypertriglyceridemia in up to 67% of patients receiving
asparaginase treatment for ALL [95].
Data from patients treated on the DCOG ALL-10
protocol showed a significant positive relationship
between asparaginase activity levels and triglyceride
levels [46]. This study prospectively evaluated the
incidence and clinical course of hypertriglyceridemia
and hypercholesterolemia in 89 pediatric patients
undergoing prolonged asparaginase therapy.
Hypertriglyceridemia (grade 3/4) was more prevalent in
patients receiving PEG-asparaginase compared with
patients administered Erwinia asparaginase (47% vs.
0%, respectively) [46]. Additionally, hypercholesterol-
emia (grade 3/4) was reported in 25% of patients
receiving PEG-asparaginase compared with no patients
administered Erwinia asparaginase. In this study, aspar-
aginase activity levels were consistently higher in
patients receiving PEG-asparaginase compared with
patients receiving Erwinia asparaginase, possibly con-
tributing to the greater incidence of hypertriglyceride-
mia and hypercholesterolemia.
Hypertriglyceridemia is often transient and asymp-
tomatic in patients. Adjustments in asparaginase therapy
are generally not required; however, patients with
elevated triglyceride levels should be closely monitored
for signs of pancreatitis [Table I] [46,93,95,96]. Several
treatment approaches have been reported for patients
with hypertriglyceridemia, including short-term fasting
or low-fat diet, oral fibrates, omega-3, and plasmapher-
esis [47,97–101]. Strong evidence for any specific option
is lacking, and there is currently no standard treatment
for hypertriglyceridemia. Tong and colleagues [102]
reported the successful resolution of severe hypertrigly-
ceridemia in a pediatric patient by temporarily omitting
dexamethasone courses without any further changes to
therapy.
Hepatic toxicity
Hepatic toxicity associated with asparaginase use is
rarely associated with fatal complications; however,
clinical outcomes may be negatively affected if signifi-
cant delays in treatment are required due to asparagi-
nase-associated dysfunction. Asparaginase use is more
commonly associated with abnormalities in liver func-
tion and hepatic transaminases as well as elevations in
bilirubin and alkaline phosphates [7]. The mechanism of
action by which asparaginase causes hepatic dysfunc-
tion is unknown; however, the reduction in protein
synthesis associated with asparaginase therapy is
believed to play a role [40]. The degree to which hepatic
dysfunction in patients undergoing treatment for ALL
can be attributed to asparaginase use is unclear, as many
regimens include the use of several potentially hepato-
toxic drugs (e.g. corticosteroids, vinca alkaloids, anthra-
cyclines, and antimetabolites). Elevated levels of hepatic
transaminase, alkaline phosphatase, and bilirubin have
been reported in 30–60% of patients receiving aspar-
aginase as part of multiagent therapy for ALL [40,95]. In a
study of 118 children receiving native E. coli asparagi-
nase or PEG-asparaginase, abnormal liver function
(grade 3/4), including elevated transaminases and
hyperbilirubinemia, was found in 8% of patients receiv-
ing native E. coli asparaginase and in 5% of patients
receiving PEG-asparaginase [24,103,104]. In children and
adults receiving Erwinia asparaginase, grade 3/4 liver
toxicity has been reported in approximately 4% of
patients [14,33,34,105]. There are no clear pediatric
guidelines for the management of asparaginase in
patients with hepatic toxicity, and treatment recom-
mendations vary across protocols. In the DCOG ALL-11
pediatric protocol, patients are required to display
aspartate aminotransferase/alanine aminotransferase
510ULN and no signs of jaundice with bilirubin
53ULN prior to starting asparaginase treatment [106].
Recommendations for adolescent and young adults
752 N. HIJIYA & I. M. VAN DER SLUIS
(AYA) call for witholding asparaginase in patients with
grade 3/4 hepatotoxicity (alanine or glutamine amino-
transferase elevation 45ULN) with the option to
rechallenge patients with careful monitoring if
complications resolve [Table I] [40].
Toxicity in AYA patients
The treatment of AYA patients (16–39 years of age)
diagnosed with ALL represents a unique challenge.
Older patients are believed to be at a greater risk for
asparaginase-associated toxicities, and therefore, many
adult protocols limit asparaginase use [107]. However, a
number of retrospective studies have reported signifi-
cantly greater long-term survival when AYA patients are
included in pediatric protocols, which use high-intensity
asparaginase therapy [108–112]. A large prospective
study, C10403, evaluated the feasibility of using a
pediatric regimen in 318 AYA patients (16–39 years of
age) treated by adult hematologists and oncologists
[113]. Safety and toxicity results were compared with
data from AYA patients (16–21 years of age) treated on
the pediatric Children’s Oncology Group AALL0232 trial.
The rates of adverse events were relatively similar in the
two study populations, and overall treatment-related
mortality was low (3%) in the C10403 study.
Investigators concluded that treatment with a pediatric
regimen was feasible in AYA patients up to 40 years of
age [113]. Differences in toxicities between age groups
were not evaluated in C10403; however, results from
another recent trial suggest a similar safety profile in
pediatric and AYA patients. In this compassionate-use
trial, 147 AYA patients (16 to540 years of age) were
switched to Erwinia asparaginase following hypersensi-
tivity to an E. coli–derived asparaginase [34]. Rates of
asparaginase-related toxicity were reportedly similar in
AYA patients and in patients 516 years of age.
Hypersensitivity to Erwinia asparaginase was reported
in 10.9% of patients 16 years of age compared with
15.1% in patients 10 years of age. Overall, toxicities
were manageable, and the majority of AYA
patients (73%) were able to complete their
planned course of asparaginase therapy with Erwinia
asparaginase [34].
Conclusions
Asparaginase is a critical component of all pediatric ALL
protocols and is increasingly used to treat AYA patients.
With many protocols incorporating prolonged and high-
intensity asparaginase treatment, it is important that
practitioners be aware of all potential treatment-related
toxicities. Effective management of asparaginase toxicity
will help ensure patients receive their complete course
of asparaginase therapy and obtain optimal treatment
outcomes.
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